Our funds
The fund

Fondita Healthcare is an actively managed, global healthcare fund. In line with the Article 9 sustainability rating, the fund’s social sustainability objective is to invest in companies that promote health and well-being, as well as access to healthcare and equality in their own business operations.

Healthcare

The fund invests in companies that address current and unmet medical needs and provide access to medicine and medical care. This is achieved by investing in companies active in innovation, production and distribution of medicines and healthcare equipment, tools and supplies as well as diagnostics and healthcare services. Operationally, the companies are to act in a socially and environmentally responsible way.

Healthcare is an incredibly interesting, structurally growing sector and one of the three megatrends that Fondita’s thematic funds invest in.

Demographic changes with an ageing population, as well as increased welfare, translate into growing demand for healthcare. Innovation and technological advances improve care and deliver new products to fulfil current and unmet demand fueling the sector’s growth.

Sustainability
Read more about the fund’s sustainability principles:
Fund facts

31.1.2024

Fund size (M€)
50,0
ISIN (A)
FI4000321088
ISIN (B)
FI4000321096
Currency
EUR
Management fee
2,00 % p.a.
Risk indicator
4/7
SFDR Classification
Article 9
Top holdings
Novo Nordisk (DK)
6,2 %
Eli Lilly (US)
6,0 %
Boston Scientific (US)
4,7 %
Stryker (US)
4,3 %
AstraZeneca (SE)
4,3 %
USA
40 %
Switzerland
20 %
Denmark
12 %
Sweden
9 %
Germany
7 %
Return
1 month
4,5 %
3 months
16,2 %
6 months
5,5 %
YTD
4,5 %
1 year
9,6 %
3 years
3,6 %
5 years
52,6 %
since launch (14.6.2018)
46,4 %
since launch p.a.
7,0 %
Sector division
Pharma
58 %
Healthcare Equipment
40 %
Consumer Discretionary
0 %
Cash
2 %
Top 10 holdings
Novo Nordisk (DK)
6,2 %
Eli Lilly (US)
6,0 %
Boston Scientific (US)
4,7 %
Stryker (US)
4,3 %
AstraZeneca (SE)
4,3 %
Hologic (US)
3,8 %
Medtronic (US)
3,6 %
Siegfried Holding (CH)
3,5 %
Unitedhealth Group (US)
3,2 %
Laboratorios Farma Rovi (ES)
3,2 %
Country division
USA
40 %
Switzerland
20 %
Denmark
12 %
Sweden
9 %
Germany
7 %
Finland
5 %
Other
8 %
Currency exposure
USD
40 %
CHF
20 %
EUR
18 %
DKK
12 %
SEK
9 %
GBP
2 %
Fees
TER
2,00 %
Subscription fee
0,00 %
Redemption fee
1,00 %

Total client relationship allow for changes in tariff rate.

Documents

FUND INFORMATION
KID
PAI Statements
Fund rules
KID I
KID NO
Prospectus
REPORTS
Monthly report
Annual report
SUSTAINABILITY DOCUMENTS
ESG Report
Responsible Investment Policy

This is marketing communication. The past performance of the investment fund does not provide any guarantee of future results. Read the fund prospectus and KID (Key Information Document) before making any investment decisions. The fund prospectus and KID are available on English, Finnish and Swedish at our website.

Our funds
Latest news
Turnaround for small caps in 2024?

2023 turned out to be a good year for large caps in general, in the US led by the megacap stocks, whereas ... Read more

Fondita’s Head of ESG elected to the board of Finsif starting 2024

Our Head of ESG, Erik Wikström, has been elected to the board of Finsif for 2024! Finsif promotes responsible investments that take ... Read more

This page was last updated

Web design: Wikström Media
Fondita online Fondita
online